Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells

[1]  Zhilan Peng,et al.  MG132, a proteasome inhibitor, induces apoptosis in tumor cells , 2013, Asia-Pacific journal of clinical oncology.

[2]  Jennifer L. Thompson.  Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma , 2013, The Annals of pharmacotherapy.

[3]  C. Moskaluk,et al.  Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  K. O'Byrne,et al.  Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  D. Hanseman,et al.  Prospective Evaluation of the Toxicity Profile of Proteasome Inhibitor–Based Therapy in Renal Transplant Candidates and Recipients , 2012, Transplantation.

[6]  J. Baehring,et al.  Glioblastoma multiforme: overview of current treatment and future perspectives. , 2012, Hematology/oncology clinics of North America.

[7]  I. Rosas,et al.  Autophagy in Idiopathic Pulmonary Fibrosis , 2012, PloS one.

[8]  H. Saya,et al.  Molecular biology of glioma. , 2012, Advances in experimental medicine and biology.

[9]  R. Perez-soler,et al.  Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  J. Pignon,et al.  Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. , 2012, Lung cancer.

[11]  A. Shanker,et al.  Development of Proteasome Inhibitors as Therapeutic Drugs. , 2012, Journal of clinical & cellular immunology.

[12]  S. Bhaumik,et al.  The 26S proteasome complex: an attractive target for cancer therapy. , 2012, Biochimica et biophysica acta.

[13]  S. Leenstra,et al.  Recent advances in the molecular understanding of glioblastoma , 2009 .

[14]  Q. Dou,et al.  Advances in the understanding of mechanisms and therapeutic use of bortezomib. , 2011, Discovery medicine.

[15]  S. Qiu,et al.  Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis , 2011, Autophagy.

[16]  Jia Fan,et al.  Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation , 2011, Clinical Cancer Research.

[17]  I. Pollack,et al.  Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling Pathway , 2011, Molecular Cancer Therapeutics.

[18]  A. Wen,et al.  Autophagy is a therapeutic target in anticancer drug resistance. , 2010, Biochimica et biophysica acta.

[19]  K. Dalby,et al.  Targeting the pro-death and pro-survival functions of autophagy as novel therapeutic strategies in cancer , 2010, Autophagy.

[20]  S. Pédeboscq,et al.  Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. , 2008, Journal of experimental therapeutics & oncology.

[21]  J. Cleveland,et al.  Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. , 2007, Blood.

[22]  G. Evan,et al.  Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. , 2007, The Journal of clinical investigation.

[23]  Kevin Bray,et al.  Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. , 2006, Cancer cell.

[24]  M. Boccadoro,et al.  Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies , 2006, Nature Clinical Practice Oncology.

[25]  M. Carducci,et al.  Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Rafael Fonseca,et al.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Giaccone,et al.  Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.

[28]  Junying Yuan,et al.  Autophagy in cell death: an innocent convict? , 2005, The Journal of clinical investigation.

[29]  P. Elliott,et al.  Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Chauhan,et al.  Proteasome inhibition in multiple myeloma: therapeutic implication. , 2005, Annual review of pharmacology and toxicology.

[31]  T. Sayers,et al.  Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy , 2005, Cancer Immunology, Immunotherapy.

[32]  K. Neville,et al.  Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. López-Otín,et al.  Autophagy: molecular mechanisms, physiological functions and relevance in human pathology , 2004, Cellular and Molecular Life Sciences CMLS.

[34]  K. Hoang-Xuan,et al.  Primary brain tumours in adults , 2003, The Lancet.

[35]  J. Shapiro.  Genetic alterations associated with adult diffuse astrocytic tumors. , 2002, American journal of medical genetics.

[36]  S. Soignet,et al.  A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  B. Pikul,et al.  Gliomas--past, present, and future. , 1999, Clinical neurosurgery.